Exciting Developments from Remix Therapeutics
WATERTOWN, Mass. — Remix Therapeutics, a pioneering clinical-stage biotechnology enterprise, is revolutionizing the world of RNA processing with its innovative therapies. This week, the company unveiled significant data from its Phase 1 clinical trial for the MYB RNA degrader, REM-422. The findings were accepted for a prominent late-breaking oral presentation during a major cancer therapeutic conference.
Presentation Highlights
The forthcoming presentation will showcase the trial's primary goals, which involve establishing the safety of REM-422, identifying dose-limiting toxicities, and determining a recommended phase 2 dose (RP2D). The study also aims to evaluate the preliminary anti-tumor effects of REM-422 on patients diagnosed with recurrent or metastatic adenoid cystic carcinoma (ACC).
Oral Presentation Details
Details regarding the oral presentation include the following:
- Title: A Phase I Trial of the MYB RNA degrader REM-422
- Presenter: Dr. Glenn J. Hanna from Dana-Farber Cancer Institute
- Date & Time: October 24; Plenary Session 4 from 10:00 - 11:40 am
- Location: Level 3, Ballroom AB
Poster Presentation Details
In addition to the oral presentation, there will be a poster session as follows:
- Title: A Phase I Trial of the MYB RNA degrader REM-422
- Presenter: Dr. Glenn Hanna
- Session and Poster Number: Poster Session B, LB-B005
- Date and Time: October 24 from 12:30 - 4:00 pm
- Location: Level 2, Exhibit Hall D
Participating in the RNA Targeting Session
In addition to their presentations, Remix Therapeutics will host a session focused on targeting RNA with small molecules. This session aims to gather leading experts and provide a platform for discussing innovative approaches in oncology.
Session Details
Here are the details of the concurrent session:
- Title: Concurrent Session 9: Targeting RNA with Small Molecules
- Co-Chair: Dr. Chris Bowden, Chief Medical Officer, Remix Therapeutics
- Presenter: Dr. Charles Kung, Vice President of Biology, Remix Therapeutics
- Featured Topic: REM-422, a first-in-class mRNA degrader of the MYB oncogene
- Date & Time: October 25 from 4:15 – 5:55 pm
- Location: Level C, Ballroom 3
About REM-422
REM-422 is an innovative oral small molecule classified as a first/best-in-class therapy. Its mechanism induces degradation of MYB mRNA, reducing protein expression through a sophisticated process that incorporates poison exons into the MYB mRNA transcript. This process results in the targeted decay of the unwanted transcript. Currently, REM-422 is being evaluated in Phase 1 clinical trials for ACC, Acute Myeloid Leukemia (AML), and high-risk myelodysplastic syndrome (HR-MDS). The U.S Food and Drug Administration has granted Orphan Drug Designation for both ACC and AML.
About Remix Therapeutics
Founded with a vision for reprogramming RNA processing, Remix Therapeutics is at the forefront of developing novel small molecule therapies. Their REMaster™ technology platform applies advanced data science and biomolecular methodologies to yield orally administered compounds that modulate gene expression. This innovative approach has led to the formulation of REM-422, now being explored in clinical studies for its potential against critical oncological diseases such as AML, HR-MDS, and ACC.
Contact Information
Media Contact:
Lisa Buffington
Buffington Comms
lbuffington@remixtx.com
Investor Contact:
Will O'Connor
Precision AQ
Will.OConnor@precisionaq.com
Frequently Asked Questions
What is REM-422?
REM-422 is a first-in-class, oral small molecule mRNA degrader developed by Remix Therapeutics designed to reduce MYB mRNA and protein expression.
What are the primary objectives of the Phase 1 trial?
The trial aims to determine the safety profile, any dose-limiting toxicities, and to define a recommended phase 2 dose (RP2D).
Who is the presenter at the oral session?
Dr. Glenn J. Hanna from the Dana-Farber Cancer Institute will present the findings.
What diseases is REM-422 targeting?
REM-422 is being investigated for its efficacy in treating recurrent or metastatic adenoid cystic carcinoma (ACC) and other critical cancers like Acute Myeloid Leukemia (AML).
Is REM-422 a new type of therapy?
Yes, it is considered a first/best-in-class therapy focused on modulating RNA processes to target the underlying drivers of disease.
